Estrella Immunopharma, Inc.
ESLA
$0.96
-$0.0095-0.98%
NASDAQ
| 06/30/2025 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.32% | -4.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 163.46% | 741.19% | |||
| Operating Income | -163.46% | -741.19% | |||
| Income Before Tax | -163.46% | -741.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -163.50% | -741.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -163.50% | -741.55% | |||
| EBIT | -163.46% | -741.19% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -163.86% | -719.70% | |||
| Normalized Basic EPS | -163.91% | -714.46% | |||
| EPS Diluted | -163.86% | -719.70% | |||
| Normalized Diluted EPS | -163.91% | -714.46% | |||
| Average Basic Shares Outstanding | -0.06% | 2.83% | |||
| Average Diluted Shares Outstanding | -0.06% | 2.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||